Synonyms: campath 1H | Campath® | campath-1H | Lemtrada®
alemtuzumab is an approved drug (FDA (2001), EMA (2013))
Compound class:
Antibody
Comment: CAMPATH-1 (CD52) antigen inhibitor. Functionally, alemtuzumab causes depletion and then recovery of the immune system.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. ![]() View more information in the IUPHAR Pharmacology Education Project: alemtuzumab |
Classification ![]() |
|
Compound class | Antibody |
Approved drug? | Yes (FDA (2001), EMA (2013)) |
Approved drug? | Yes. FDA (2001) | EMA (2013) |
International Nonproprietary Names ![]() |
|
INN number | INN |
8005 | alemtuzumab |
Synonyms ![]() |
campath 1H | Campath® | campath-1H | Lemtrada® |
Database Links ![]() |
|
Specialist databases | |
IMGT/mAb-DB | 11 |
Other databases | |
GtoPdb PubChem SID | 178103376 |
PubChem SID | 178103376 |
Search PubMed clinical trials | alemtuzumab |
Search PubMed titles | alemtuzumab |
Search PubMed titles/abstracts | alemtuzumab |
Wikipedia | Alemtuzumab |